GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses

DOI: 10.1080/2162402X.2015.1101204

Keywords: CD4+ effector T cells, CD8+ T cells, clinical trial, CTLA-4, GM-CSF, immunotherapy, ipilimumab, metastatic melanoma, PD-1

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text